Regeneron Pharmaceuticals Inc. has disclosed an antibody-drug conjugate consisting of exatecan covalently linked to the antibody trastuzumab targeting HER2 through a linker reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has described new dual microtubule destabilizers (tubulin polymerization inhibitors) and proto-oncogene tyrosine-protein kinase Src inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, actinic keratosis, vitiligo and systemic lupus erythematosus, among others.
The German Cancer Research Center has discovered cyclin-dependent kinase 12 (CDK12)/cyclin K inhibitors reported to be useful for the treatment of cancer.
An experimental vaccine that contained antigens of both lytic and latent phases of Epstein-Barr virus (EBV), and induced both an antibody and a T cells response, was able to generate broad and long-lasting immunity against EBV in mouse models of infection. Researchers from the QIMR Berghofer Medical Research Institute and Elicio Therapeutics Inc. reported those results online in Nature Communications on Aug. 8, 2023.
For some viruses, the challenge to developing a vaccine is their rapid mutation rate. This is the major challenge to developing an HIV vaccine or a universal flu vaccine. EBV is different. Its superpower is its ability to hide.
AGV Discovery SAS, in collaboration with scientists from Centre National de la Recherche Scientifique, Inserm and Universite de Montpellier, divulged azaindole derivatives acting as extracellular-regulated kinase (ERK) inhibitors, particularly ERK2, reported to be useful for the treatment of cancer, inflammation, autoimmune disease, substance abuse and dependence, metabolic syndrome, neurodegeneration, HIV infection, and pain, among other disorders.
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed MAP kinase-activated protein kinase 2 (MK2) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, atherosclerosis, diabetes and fibrosis, as well as metabolic and autoimmune diseases.
Dong Wha Pharmaceutical Co. Ltd. has defined histone-lysine N-methyltransferase EZH1 and/or EZH2 inhibitors reported to be useful for the treatment of cancer.
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described androgen receptor antagonists and/or androgen receptor degradation inducers reported to be useful for the treatment of gastrointestinal disorders, osteoporosis and SARS-CoV-2 infection (COVID-19), as well as breast and castration-resistant prostate cancer.
Researchers from Tokyo University of Science presented the discovery and preclinical evaluation of a novel KRAS-degrading small molecule candidate being developed for the treatment of cancer.
RSS
